According to Oncotarget, Particular negative breast cancer cells positively react to therapy involving hormones given they show an estrogen receptor beta protein as well as reveal other molecules expected to develop breast cancer drugs. The breast cancer cells contain types of progesterone and or estrogen hormones that contribute to their growth. The absence of receptors for these hormones causes resistance to hormonal treatment which causes Triple Negative Breast Cancer. Follow Oncotarget on Twitter.
The success of Oncotarget has prompted us to launch sections beyond oncology – https://t.co/ccRO4O68Oj
— Oncotarget (@OncotargetJrnl) December 14, 2017
Patients with this condition are underprivileged since cancer can spread to other body organs. The Mayo Clinic researchers found out that the TNBC cells with no estrogen alpha receptor could be decelerated with estrogen chemicals if the cells show another estrogen receptor. They also found that estrogen could prevent tumor growth if the cells got expressed, and estrogen impact on estrogen receptor beta protein is because of cyclin-dependent kinases, proteins that control the cell division. Download output styles at Endnote.com
The researchers’ preliminary study observed that TNBC patients lacking estrogen receptor alpha proteins have high endurance rate and capable of becoming cancer free. Oncotarget is a public biomedical journal. It researches on oncology and beyond Including immunology, aging, microbiology, autophagy, chromosomes, and pathology.
Oncotarget currently publishes two productions a week accessible on top most scientific research catalogs and other documents as well as in PubMed. The Oncotarget team announced to the readers its commitment to consistently make available their publications in PubMed and relevant archives and indexes. In association with National Library of Medicine, it is attaining its goal of being the first research journal to post to PubMed complete findings immediately after publishing.
Oncotarget association with high profile researchers has enabled them to make the prompt availability of their scientific findings to medical practitioners, field researchers, and the public. It has since 2010 produced 324 publications and it is now in the eighth volume. It gives a Direct Object Identifier to every paper and applies the committee recommendations on public ethics. The Oncotarget mission is to remain a prominent academic journal recognized for its rapid and extensive spread bio-medical research. It Strives to fight disease and by assisting researchers to contribute to the development of science.
Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/